Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL322 Target Snapshot

5-hydroxytryptamine receptor 2A · SINGLE PROTEIN · Rattus norvegicus

2,527Compounds
407Assays
29Approved Drugs
3,024.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P14842. Use UniProt P14842 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P14842 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 2A as ChEMBL target CHEMBL322, mapped to UniProt P14842. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 2A
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL322
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14842
5-hydroxytryptamine receptor 2A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 2A is the right protein anchor across sources, using UniProt P14842 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 2A
UniProt AccessionP14842
Component TypeProtein
Sequence Length471 aa

5-hydroxytryptamine receptor 2A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 2A, mapped to UniProt P14842. Sequence length is 471 aa.

Mapped IDP14842
Review name5-hydroxytryptamine receptor 2A
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

29
Approved
10
Phase III
35
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50541.0
KI2,258.0
EC50135.0
KD90.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3763812 10.9 Ki 0.0126 Preclinical
CHEMBL1927096 10.79 Ki 0.0161 Preclinical
CHEMBL1927096 10.66 IC50 0.0217 Preclinical
CHEMBL4205290 10.65 Ki 0.0224 Preclinical
CHEMBL3763474 10.41 Ki 0.039 Preclinical
CHEMBL3617113 10.37 Ki 0.043 Preclinical
CHEMBL3765231 10.34 Ki 0.046 Preclinical
CHEMBL83894 10.22 Ki 0.06 Clinical
CHEMBL74355 10.0 Ki 0.1 Clinical
CHEMBL6607 10.0 Ki 0.1 Clinical
Distribution

pChEMBL Value Distribution

134
5.0
225
5.5
336
6.0
400
6.5
370
7.0
343
7.5
299
8.0
185
8.5
130
9.0
61
9.5
pChEMBL
Approved Drugs

Approved Drugs

BREXPIPRAZOLE
CHEMBL2105760
Approved 2015
LURASIDONE
CHEMBL1237021
Approved 2010
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
ZIPRASIDONE
CHEMBL708
Approved 2001
QUETIAPINE
CHEMBL716
Approved 1997
SERTINDOLE
CHEMBL12713
Approved 1996
OLANZAPINE
CHEMBL715
Approved 1996
MIRTAZAPINE
CHEMBL654
Approved 1996
NEFAZODONE
CHEMBL623
Approved 1994
RISPERIDONE
CHEMBL85
Approved 1993
CLOZAPINE
CHEMBL42
Approved 1989
BUSPIRONE
CHEMBL49
Approved 1986
TRAZODONE
CHEMBL621
Approved 1981
LOXAPINE
CHEMBL831
Approved 1975
HALOPERIDOL
CHEMBL54
Approved 1967
METHYSERGIDE
CHEMBL1065
Approved 1962
CYPROHEPTADINE
CHEMBL516
Approved 1961
Assay Landscape

Assay Landscape

407
Total Assays
2,054
Tested Compounds
3
Assay Types
Binding — 344 assays, 2,054 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 106 384 7.2
assay format 89 651 7.1
tissue-based format 77 584 7.3
cell membrane format 43 241 7.0
cell-based format 26 194 7.5
organism-based format 3 0
Functional — 60 assays, 168 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 23 33 6.4
tissue-based format 21 86 7.8
cell-based format 15 49 7.0
organism-based format 1 0
ADME — 3 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 7.2
tissue-based format 1 1 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine